Free tool
FAERS Monitor: Natazia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022252 or its brand name (Natazia, Dienogest, Estradiol Valerate). Reports on generic versions are filed under their own applications.
Reports
322
Serious
63
20% of reports
Hospitalization
19
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- metrorrhagia35
- drug dose omission34
- headache18
- vaginal haemorrhage15
- off label use14
- menstruation delayed12
- pregnancy on oral contraceptive12
- nausea11
- product use issue11
- amenorrhoea10
- product use in unapproved indication10
- inappropriate schedule of drug administration9
- vomiting9
- abnormal withdrawal bleeding8
- menorrhagia8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 42 |
| 2012 | 43 |
| 2013 | 40 |
| 2014 | 26 |
| 2015 | 32 |
| 2016 | 22 |
| 2017 | 10 |
| 2018 | 16 |
| 2019 | 18 |
| 2020 | 13 |
| 2021 | 8 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,837 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal withdrawal bleedingSignal | 8 | 573.5 | 288.4 | 3,983 |
| pregnancy on oral contraceptiveSignal | 12 | 300.4 | 172.2 | 3,273 |
| metrorrhagiaSignal | 35 | 134.3 | 98.2 | 4,494 |
| menstruation delayedSignal | 12 | 72.4 | 41.5 | 775 |
| amenorrhoeaSignal | 10 | 37.3 | 20.2 | 318 |
| menorrhagiaSignal | 8 | 26.6 | 13.4 | 173 |
| vaginal haemorrhageSignal | 15 | 22.6 | 13.8 | 289 |
| drug dose omissionSignal | 34 | 13.4 | 9.8 | 382 |
| inappropriate schedule of drug administrationSignal | 9 | 8.3 | 4.3 | 51 |
| product use issueSignal | 11 | 3.8 | 2.1 | 20 |
| product use in unapproved indicationSignal | 10 | 2.6 | 1.4 | 9 |
| headache | 18 | 1.9 | 1.2 | 7 |
| vomiting | 9 | 1.3 | 0.7 | 0 |
| off label use | 14 | 1.0 | 0.6 | 0 |
| nausea | 11 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.